(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.43%.
Cervomed's earnings in 2026 is -$30,036,491.On average, 9 Wall Street analysts forecast CRVO's earnings for 2026 to be -$25,377,223, with the lowest CRVO earnings forecast at -$39,379,184, and the highest CRVO earnings forecast at -$17,012,896. On average, 8 Wall Street analysts forecast CRVO's earnings for 2027 to be -$22,429,247, with the lowest CRVO earnings forecast at -$41,738,305, and the highest CRVO earnings forecast at -$13,221,451.
In 2028, CRVO is forecast to generate -$21,972,792 in earnings, with the lowest earnings forecast at -$30,940,787 and the highest earnings forecast at -$11,763,202.